Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders
Status:
Active, not recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral
immune response against the aquaporin-4(AQP-4) water channel. Belimumab (Benlysta ®) is a
human immunoglobulin G1λ monoclonal antibody that inhibits B-cell survival and
differentiation by neutralizing soluble B lymphocyte stimulator. Belimumab may benefit some
patients with NMOSD due to the important role of B cells in the pathogenesis of NMOSD.
Clincial trials may be needed to observe its efficacy and safety.